article 3 months old

C’mon Pentax!

Australia | Apr 20 2006

In recent years possibly the most hyped medical product related to the Australian equity market has been the retractable syringe, the headlines produced being inversely proportional to the revenues being generated from the product. This means far less attention has been afforded to companies with proven technologies that are generating or set to generate significant revenues for the companies that have developed them.

One such company is Optiscan Imaging (OIL), which is viewed by Intersuisse as a world leader in microscopy technology. The company has developed the miniaturised flexible endoscope, which is being marketed though a partnership with Pentax. This relationship now appears set to pay dividends for Optiscan shareholders.

Where the company has an advantage is its product offers the highest degree of magnification and resolution available on the world market, a market estimated to be worth about US$1.2bn.

Sales look set to pick up, as Pentax will begin an aggressive marketing campaign on the product to doctors globally. A conference next month is one such opportunity, with Intersuisse suggesting the sales response is likely to be positive given the positive reaction to the device at the same conference last year.

The broker notes the company benefits from the fact the endoscope has a life of two to three years before it needs replacing, the usual purchase being two such devices and a controller box, which has a total cost of about $150,000.

Optiscan’s agreement with Pentax will see the company receive $2-$4,000 for the scope components, $13-18,000 per box and a 7.5-10% royalty on each scope sold, the broker estimating it requires sales of 200 units annually to break-even.

Assuming Pentax’s marketing efforts are successful, and given Pentax is attempting to take market share from Olympus a commitment to a full marketing effort seems assured, the difference in revenue and earnings terms for Optiscan could be significant.

The company reported revenue for the half year to December 31 of about $1.88m, while its loss for the period was around $2.2m. While cash on hand of $8.6m is enough to fund its immediate needs, revenue from sales of the device would quickly transform the company’s balance sheet.

The company is also exploring other growth markets, one being the rigid endoscope market, estimated to be of similar size to the flexible market.

Optiscan has about 100m shares on issue and has traded between $0-28-$0.55 in the past 12 months.

Only one broker and equity researcher in the FN Arena database covers the stock, rating it a Speculative Accumulate at prices around $0.35.

The last sale price for the stock was $0.50.

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.